The Financial Times reports that BD (NYSE: BDX)+ began discussions with a handful of competitors for the sale of its Life Sciences business. In February, the BD board unanimously authorized management to pursue the separation of its Life Sciences business. According to FT, BD entered talks with Thermo Fisher and Danaher to discuss the potential sale of the business. The company is also considering a “Reverse Morris” trust tax-free deal, FT says. Waters, Qiagen and Revvity are all potential candidates for that type of deal, according to the report, which cited sources familiar with the matter.
Read the full article: Report: BD Is in Talks with Competitors to Sell Life Sciences Biz //
Source: https://www.massdevice.com/report-bd-talks-sell-life-sciences/